Tralokinumab shows promise as long-term treatment for head, neck atopic dermatitis
Click Here to Manage Email Alerts
Key takeaways:
- IGA 0/1 was reached by 59% and 53% of dupilumab-naïve and dupilumab-experienced patients, respectively, at 9 months.
- Of the respective groups, 70% and 100% reported meaningful quality of life improvements. .
Nearly half of patients with head and neck atopic dermatitis who were treated with tralokinumab reported disease clearance after 9 months, according to a presentation at the European Academy of Dermatology and Venereology Congress.
“This is oftentimes thought of as the most challenging areas to treat,” April W. Armstrong, MD, MPH, professor and chief of dermatology at University of California, Los Angeles, said during her presentation on TRACE, a noninterventional, single cohort, real-world, 12-month study.
In the study, researchers observed 824 tralokinumab-treated adult patients with AD, 655 of which had AD on the head and neck.
“Overall, in the cohort of patients across several different countries in the real world starting with tralokinumab, about 80% will have some form of head and neck atopic dermatitis,” Armstrong said, emphasizing the importance of finding treatment options for this area.
Among these 655 patients, 501 were dupilumab-naïve. The presentation touched on interim data through 9 months of treatment.
Results showed that after 3 months of treatment, the proportion of patients reporting head and neck AD decreased from 100% to 67% across patient groups. By month 6 and 9, these proportions decreased further to 58% and 52%, respectively.
IGA 0/1 was reached by 59% and 53% of dupilumab-naïve and dupilumab-experienced patients, respectively, at the end of 9 months. A 2-point improvement in IGA-assessed disease severity was also achieved by 75% and 63% of dupilumab-naïve and dupilumab-experienced patients in the same time frame.
All dupilumab-experienced patients reported a meaningful improvement in their quality of life by month 9 compared with 70% of dupilumab-naïve patients. Similar proportions of patients in both groups reported improvement in patient-reported eczema control by month 9 (46% and 44%).